Clinical Trials in Milan, MI
211 recruiting
Showing 1–20 of 153 trials
Recruiting
Phase 1Phase 2
A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC
PSMA-positive Metastatic Castration Resistant Prostate Cancer (mCRPC) With Prior Exposure to One Prior ARPI Who Are Candidates for Taxane-based Chemotherapy
Novartis Pharmaceuticals123 enrolled19 locationsNCT07226986
Recruiting
Phase 2Phase 3
Alpelisib in Pediatric and Adult Patients With Lymphatic Malformations Associated With a PIK3CA Mutation.
Lymphatic Malformations
Novartis Pharmaceuticals232 enrolled57 locationsNCT05948943
Recruiting
Master Framework For Relapse or Refractory Acute Myeloid Leukemia
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia, Refractory
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS4,000 enrolled38 locationsNCT06459024
Recruiting
Phase 2
18F FES-PET/MRI for Tailoring Treatment of Luminal A and Lobular Breast Cancer
Breast Cancer FemaleLobular Breast CarcinomaPET/MRI+2 more
Università Vita-Salute San Raffaele119 enrolled1 locationNCT05982496
Recruiting
Phase 3
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals5,700 enrolled618 locationsNCT07517263
Recruiting
Phase 4
Asciminib Roll-over Study
Chronic Myelogenous LeukemiaLeukemia, Myelogenous, Chronic, BCR-ABL Positive
Novartis Pharmaceuticals347 enrolled85 locationsNCT04877522
Recruiting
Phase 4
Pediatric Long-Term Follow-up and Rollover Study
Neurofibromatosis Type 1GlioblastomaAnaplastic Astrocytoma+20 more
Novartis Pharmaceuticals165 enrolled55 locationsNCT03975829
Recruiting
Phase 2
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Geographic Atrophy secondary to Age Related Macular Degeneration
Novartis Pharmaceuticals272 enrolled28 locationsNCT07441642
Recruiting
Phase 2
A Clinical Study to Evaluate Ianalumab in Participants With Diffuse Cutaneous Systemic Sclerosis
Diffuse Cutaneous Systemic Sclerosis
Novartis Pharmaceuticals200 enrolled128 locationsNCT06470048
Recruiting
Insights From the FAST-TRACK CABG Trial: a Clinical Outcome Study in Patient With Previous Surgical Revascularization for Complex Three-vessel or Left Main Coronary Artery Disease Based on Coronary Computed Tomography Angiogram, and Fractional Flow Reserve Derived by Computed Tomography
Multivessel Coronary Artery Disease
Centro Cardiologico Monzino100 enrolled1 locationNCT07628270
Recruiting
Phase 1Phase 2
Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors
Advanced HR+/HER2- Breast CancerAdvanced CCNE1-amplified Solid TumorsMetastatic Castration-resistant Prostate Cancer
Novartis Pharmaceuticals205 enrolled9 locationsNCT07288359
Recruiting
Phase 1Phase 2
An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01)
Progressive Metastatic Castrate Resistant Prostate Cancer
Novartis Pharmaceuticals188 enrolled32 locationsNCT07206056
Recruiting
Phase 2
Phase 2 Study Evaluating Rapcabtagene Autoleucel in Participants With Diffuse Cutaneous Systemic Sclerosis
Scleroderma, Diffuse
Novartis Pharmaceuticals96 enrolled87 locationsNCT06655896
Recruiting
Phase 2
A Study of Rapcabtagene Autoleucel in Active, Refractory Systemic Lupus Erythematosus (SLE) or Lupus Nephritis (LN) Patients (AUTOGRAPH - SLE/LN)
Lupus Erythematosus, SystemicLupus Nephritis
Novartis Pharmaceuticals179 enrolled101 locationsNCT06581198
Recruiting
Phase 2
Phase 2 Study of Rapcabtagene Autoleucel in Myositis
Idiopathic Inflammatory Myopathies
Novartis Pharmaceuticals123 enrolled68 locationsNCT06665256
Recruiting
Phase 3
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals360 enrolled106 locationsNCT06846281
Recruiting
Phase 3
Study of Efficacy and Safety of Iptacopan in Participants With IC-MPGN
IC-MPGN
Novartis Pharmaceuticals106 enrolled130 locationsNCT05755386
Recruiting
Phase 3
Study of Efficacy and Safety of Iptacopan in Patients With C3 Glomerulopathy.
C3G
Novartis Pharmaceuticals98 enrolled87 locationsNCT04817618
Recruiting
Phase 1Phase 2
An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
Relapsing Multiple Sclerosis
Novartis Pharmaceuticals28 enrolled18 locationsNCT06617793
Recruiting
Changing Paragidms In The Prognostic Assessment Of Hodgkin Lymphoma
Classical Hodgkin LymphomaClassical Hodgkin Lymphoma RecurrentClassical Hodgkin Lymphoma Refractory
Azienda USL Reggio Emilia - IRCCS755 enrolled12 locationsNCT06822855